[1]顾 清,张 莉,张新星,等.抑制ERBB2基因对肝癌HepG2细胞生长及PI3K/AKT信号通路的影响[J].郑州大学学报(医学版),2019,(01):19-23.[doi:10.13705/j.issn.1671-6825.2018.10.102]
 GU Qing,ZHANG Li,ZHANG Xinxing,et al.Inhibition of ERBB2 gene on hepatoma HepG2 cell growth and PI3K/AKT signaling pathway[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2019,(01):19-23.[doi:10.13705/j.issn.1671-6825.2018.10.102]
点击复制

抑制ERBB2基因对肝癌HepG2细胞生长及PI3K/AKT信号通路的影响()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2019年01期
页码:
19-23
栏目:
论著
出版日期:
2019-01-20

文章信息/Info

Title:
Inhibition of ERBB2 gene on hepatoma HepG2 cell growth and PI3K/AKT signaling pathway
作者:
顾 清张 莉张新星代小松陈和平
四川省医学科学院(四川省人民医院)老年消化科 成都 610072
Author(s):
GU QingZHANG LiZHANG XinxingDAI XiaosongCHEN Heping
Department of Gastroenterology, Sichuan Academy of Medical Sciences(Sichuan Provincial People's Hospital), Chengdu 610072
关键词:
ERBB2基因 肝癌 HepG2细胞 细胞生长 PI3K/AKT信号通路
Keywords:
ERBB2 gene liver cancer HepG2 cell cell growth PI3K/AKT signaling pathway
分类号:
R735.7
DOI:
10.13705/j.issn.1671-6825.2018.10.102
摘要:
目的:探讨抑制ERBB2基因表达对肝癌HepG2细胞生长及PI3K/AKT信号通路的影响。方法:采用脂质体法将ERBB2 siRNA转染至肝癌HepG2细胞,记为实验组(ERBB2-siRNA组),以siRNA 对照转染的细胞记为阴性对照组(Con-siRNA组),将不经任何处理的细胞记为空白对照组。采用qRT-PCR和Western blot法检测转染效率,CCK-8法检测细胞增殖能力,克隆形成实验检测细胞克隆形成能力,流式细胞仪检测细胞周期,Western blot法检测HepG2细胞中增殖细胞核抗原(PCNA)、AKT和p-AKT蛋白表达水平。结果:在HepG2细胞中转染ERBB2 siRNA能够抑制ERBB2的表达(P<0.05)。与Con-siRNA组比较,抑制ERBB2的表达后细胞生长和克隆形成能力明显被抑制,细胞周期发生G0/G1期阻滞,细胞中PCNA和p-AKT蛋白表达下调,差异均有统计学意义(P<0.05)。结论:抑制ERBB2基因表达可抑制肝癌HepG2细胞的生长,其作用机制可能与PI3K/AKT信号通路的激活有关。
Abstract:
Aim:To investigate the effect of inhibiting the expression of ERBB2 gene on the growth of HepG2 cells and PI3K/AKT signaling pathway.Methods:The ERBB2 siRNA was transfected into HepG2 cells by liposome method, which was recorded as the experimental group(ERBB2-siRNA group). The cells transfected with siRNA control were recorded as negative control group(Con-siRNA group), the cells without any treatment were recorded as blank control group. The transfection efficiency was detected by qRT-PCR and Western blot, the cell proliferation ability was detected by CCK-8 method, the cell clone formation ability was detected by colony formation assay, and the cell cycle was detected by flow cytometry. Proliferating cell nuclear antigen(PCNA), AKT and p-AKT protein levels were measured in HepG2 cells by Western blot.Results:Transfection of ERBB2 siRNA in HepG2 cells inhibited the expression of ERBB2(P<0.05). Compared with the Con-siRNA group, the cell growth and colony formation abilities were significantly inhibited after reducing the expression of ERBB2(P<0.05). The cells arrested at G0/G1 phase and the expressions of PCNA and p-AKT proteins in the cells were down-regulated(P<0.05).Conclusion:Inhibition of ERBB2 gene expression could inhibit the growth of HepG2 cells, and its mechanism is related to the activation of PI3K/AKT signaling pathway.

参考文献/References:

[1] MCGLYNN KA,HAGBERG K,CHEN J,et al.Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink[J].Int J Cancer,2016,138(9):2146
[2] YIM SY,SEO YS,JUNG CH,et al.The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?[J].Liver Int,2016,36(3):445
[3] FAHRNER R,THEIS B,ARDELT M,et al.Rapid progressive colon cancer metastasized to the right epididymis and liver: report of a case and review of the literature[J].Int J Colorectal Dis,2016,31(3):721
[4] LIN SL,WU SM,CHUNG IH,et al.Stimulation of interferon-stimulated gene 20 by thyroid hormone enhances angiogenesis in liver cancer[J].Neoplasia,2018,20(1):57
[5] GROENENDIJK FH,DE JONG J,VAN DE PUTTE EE,et al.ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy[J].Eur Urol,2016,69(3):384
[6] ROSS JS,GAY LM,WANG K,et al.Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: an emerging opportunity for anti-HER2 targeted therapies[J].Cancer,2016,122(17):2654
[7] AKCAY T,YASAR O,KUSEYRI MA,et al.Significance of serum c-erbB-2 oncoprotein, insulin-like growth factor-1 and vascular endothelial growth factor levels in ovarian cancer[J].Bratisl Lek Listy,2016,117(3):156
[8] SKRYPEK N,VASSEUR R,VINCENT A,et al.The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2[J].Oncotarget,2015,6(13):10853
[9] ZHU P,DAVIS M,BLACKWELDER AJ,et al.Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models[J].Cancer Prev Res(Phila),2014,7(2):199
[10]SHAN X,WEN W,ZHU DX,et al.miR 1296-5p inhibits the migration and invasion of gastric cancer cells by repressing ERBB2 expression[J].PLoS One,2017,12(1):e0170298
[11]LI BS,ZUO QF,ZHAO YL,et al.MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival[J].Oncogene,2015,34(20):2556
[12]KEBENKO M,DRENCKHAN A,GROS SJ,et al.ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts[J].Cell Signal,2015,27(2):373
[13]ZHU WJ,CHEN X,WANG YW,et al.MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway[J].Oncotarget,2017,8(52):89631
[14]POLIVKA J,JANKU F.Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J].Pharmacol Ther,2014,142(2):164
[15]LIU J,AHIEKPOR A,LI L,et al.Increased expression of ErbB-2 in liver is associated with hepatitis B x antigen and shorter survival in patients with liver cancer[J].Int J Cancer,2009,125(8):1894
[16]崔文豪,李成浩,朴熙绪,等.ErbB2基因rs1058808位点多态性与延边地区HBV相关肝细胞肝癌的关系及民族差异[J].山东医药,2017,57(10):5
[17]BOLOGNA-MOLINA R,MOSQUEDA-TAYLOR AA,MORI-ESTEVEZ AD,et al.Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors[J].Med Oral Patol Oral Cir Bucal,2013,18(2):E174
[18]HIRAI M,ARITA Y,MCGLADE CJ,et al.Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation[J].J Clin Invest,2017,127(2):569
[19]MA H,YIN CY,ZHANG YA,et al.ErbB2 is required for cardiomyocyte proliferation in murine neonatal hearts[J].Gene,2016,592(2):325
[20]MILAZZO FM,ANASTASI AM,CHIAPPARINO C,et al.AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies[J].Oncotarget,2017,8(14):22590
[21]MENG J,ZHANG XT,LIU XL,et al.WSTF promotes proliferation and invasion of lung cancer cells by inducing EMT via PI3K/Akt and IL-6/STAT3 signaling pathways[J].Cell Signal,2016,28(11):1673
[22]JEYAMOHAN S,MOORTHY RK,KANNAN MK,et al.Parthenolide induces apoptosis and autophagy through the suppression of PI3K/Akt signaling pathway in cervical cancer[J].Biotechnol Lett,2016,38(8):1251
[23]LI S,MA YM,ZHENG PS,et al.GDF15 promotes the proliferation of cervical cancer cells by phosphorylating AKT1 and Erk1/2 through the receptor ErbB2[J].J Exp Clin Cancer Res,2018,37(1):80

相似文献/References:

[1]尹咪咪,张建华#,张萍萍.基于BP算法的血液指标联合检测在肝癌及肝炎诊断中的应用[J].郑州大学学报(医学版),2016,(02):190.
 YIN Mimi,ZHANG Jianhua,ZHANG Pingping.Application of blood indexes combined detection in diagnosis of liver cancer and hepatitis based on BP algorithm[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2016,(01):190.
[2]王晓东),康巧珍),王小龙),等.HP-NAP对肝癌H22荷瘤小鼠肿瘤生长的抑制作用[J].郑州大学学报(医学版),2016,(05):595.
 WANG Xiaodong),KANG Qiaozhen),WANG Xiaolong),et al.Inhibitive effect of HP-NAP on tumor growth in mice bearing hepatoma H22 tumor[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2016,(01):595.
[3]柳 严,张德林,王国良,等.shRNA介导的波形蛋白基因沉默对肝癌细胞迁移、侵袭能力的影响[J].郑州大学学报(医学版),2018,(06):743.[doi:10.13705/j.issn.1671-6825.2018.04.035]
 LIU Yan,ZHANG Delin,WANG Guoliang,et al.Effect of shRNA lentiviral mediated Vimentin gene silencing on migration and invasion of hepatocellular carcinoma cells[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2018,(01):743.[doi:10.13705/j.issn.1671-6825.2018.04.035]

备注/Memo

备注/Memo:
【基金项目】四川省干部保健委员会项目(川干研2017-236) 【作者简介】顾清,通信作者,女,1980年7月生,硕士,主治医师,研究方向:炎症性肠病及胃肠道肿瘤,E-mail:gongsihui5@163.com
更新日期/Last Update: 2019-01-20